24. Pan-genotypic response to velpatasvir and sofosbuvirin chronic hepatitis C in Kashmiri population

Abstract

Background and Aims: Efficacy and safety of Velpatasvir and Sofosbuvir combination has been shown in ASTRAL trial 1–5 in Chronic hepatitis C. We aim to evaluate the efficacy (RVR and SVR) and safety of Velpatasvir and Sofosbuvirin Chronic hepatitis C regardless of genotype in Kashmiri population. Methods: It was a prospective, open label, hospital based observational study. All patients of chronic hepatitis C regardless of type of genotype were randomized into two groups: Non-cirrhotic and Cirrhotic. Both groups weredivided further into two groups: Treatment Naive and Treatment Experienced. Non-cirrhotic patients received Velpatasvir/Sofosbuvir (100/400 mg) for 12 weeks, however treatment was extended to 24 weeks or Ribavirin was added to 12-week combination in cirrhotics. Results: Till now we have enrolled 45 patients of chronic hepatitis Csince August 2016, this is an interim data of 25 patients and the study is still going on. Females constituted 14 (56%) and males were 11 (44%). Average age was 44 years (rage 20–70 years). Out of 25 patients, 16 (64%) were non-cirrhotic and 9 (36%) were cirrhotic. 24 (96%) were treatment naïve and 1 (4%) was treatment experienced. All patients 25 (100%) achieved SVR12 both in non-cirrhotic and cirrhotics. All patients tolerated the combination well, however some patients experienced nausea (26%), headache (25%) and fatigue (21%). No patient had to discontinue therapy due to adverse drug reactions. Conclusions: Single daily dose of tablet Velpatasvir and Sofosbuvir combination is safe and effective in all types of chronic hepatitis C regardless of genotype. The authors have none to declare.